麻豆视频

Desk Research

Desk work starts by mapping how CRC screening is recommended and practiced across North America, then pulling the most dependable public data series we can reuse in the model. Sources typically include guidance and screening utilization releases from agencies such as the CDC, along with cancer burden statistics from the National Cancer Institute. We also use public health reporting from Health Canada and comparable national portals. Recommendation statements from groups such as the US Preventive Services Task Force are treated as the backbone for eligibility and interval assumptions. Clinical practice patterns are cross-checked using peer-reviewed gastroenterology and oncology journals.

From there, pricing and volume signals are compiled using public payer references, procedure coding documentation, and provider-level publications. For category revenue context, we also review company filings and investor presentations for the CRC screening test and service categories relevant to the North America definition. Paid subscriptions are used selectively for company financials and intelligence, news and financials, and patent databases to confirm product positioning and timing. This list is not exhaustive, and other public sources were used to collect inputs, validate assumptions, and clarify open questions during research.

Primary Interviews and Surveys

Primary work is used to convert guideline intent into real-world volumes, prices, and adoption patterns, which are then reconciled with desk inputs. We interview test suppliers and distributors, diagnostic laboratories, hospitals, and GI clinics. We also include payers and clinical leaders who influence screening pathways across the United States, Canada, and Mexico. When an assumption seems fragile, we recheck it with a different respondent type so the final sizing is not driven by a single viewpoint.

Distribution of primary research fieldwork respondents

Sizing is built using a top-down demand pool reconstruction tied to North America screening eligibility and the practical mix of modalities used in programs and routine care, then checked with selective bottom-up approximations from supplier and channel inputs. The model starts from population in screening age bands, applies screening rate assumptions by country, and splits volumes across stool-based tests and procedure-based screening. Pricing logic is then applied using typical payer reimbursement and out-of-pocket patterns. Where the market is service heavy (for example, colonoscopy), we treat the unit as a completed procedure, and we treat kit-based tests as completed tests. This approach helps prevent double counting across modalities.

Forecasts use scenario analysis supported by a set of variables stakeholders can explain clearly. Key inputs include guideline age cutoffs and interval patterns, screening participation rates, the stool test versus endoscopy mix, average reimbursement by modality, and the rate at which newer test formats move from early adoption into routine ordering. If country-level data is thin, the gap is handled through proxy adoption curves anchored in expert interviews, then adjusted using public utilization signals before totals are finalized.

Outputs are checked against independent signals such as procedure utilization trends, lab testing activity direction, and the implied spend per screened person. Variances are investigated before sign-off. When a number appears off, we trace it back to the driver level, usually a participation rate, a modality mix shift, or a price assumption that needs revalidation.

The work is reviewed in steps by another analyst, and any material disagreements trigger follow-up calls with respondents to confirm what changed and why. Reports are refreshed annually, and interim updates are made when major guideline changes, reimbursement shifts, or new test approvals materially alter expected demand. Before delivery, a final pass is completed so clients receive the most current view available at that time.

Published market sizes for colorectal cancer screening tests can vary even when the same region is mentioned. Each publisher draws the line differently on what counts as a screening test and how services are priced. Differences also come from the base year used, how procedure volumes are converted into value, and how quickly adoption is assumed to change after policy or guideline updates.

The table shows a spread that is mainly driven by scope and valuation logic. Some sources focus only on in vitro test kits and lab testing, while others bundle broader screening services without clearly separating follow-up diagnostics. The table also reflects country-coverage choices and refresh cadence. For example, a model that drops Mexico or keeps older reimbursement assumptions can land lower than a model that updates modality pricing and participation inputs closer to the base year.

Benchmark comparison

The spread is easier to interpret once the inclusion rules are made explicit and the model drivers are kept observable. The table highlights that, in 麻豆视频's model, North America includes the United States, Canada, and Mexico, and the value calculation counts stool-based tests alongside procedure-based screening. This shifts totals versus sources that only track in vitro tests or a smaller country set.